Sjögren's syndrome is an autoimmune disease, and its important feature is the lymphocyte infiltration of exocrine glands, including lacrimal glands. It contributes to defects of their activity and causes that one of the main manifestation of Sjögren's syndrome is dry eye. Unfortunately, the discrimination between dry eye related and non-related to Sjögren's syndrome is difficult at the initial stages of diseases. In addition, the available agents for the treatment of Sjögren's syndrome-related dry eye have limited efficacy.
Aim
The purpose of this study was to describe and emphasize differences between Sjögren's Syndrome-related dry eye and non-Sjögren's Syndrome-related dry eye together with the determination of novel therapeutic options for Sjögren's Syndrome-related dry eye.
Method
A review of the relevant papers describing characteristics of Sjögren's Syndrome-related dry eye and its therapy was conducted. This article is based on both pre-clinical and clinical evidences.
Results
On the basis of our analysis, we indicated differences between Sjögren's Syndrome-related dry eye and non-Sjögren's Syndrome-related dry eye. Moreover, there are some novel markers that could be used in the diagnosis of Sjögren's Syndrome-related dry eye. In addition, expect artificial tear, other agents e.g. hydroxychloroquine can be effective in therapy of disease.
Conclusions
Sjögren's Syndrome-related dry eye is a disorder, whose diagnosis may be difficult and mistaken for non-Sjögren's Syndrome-related dry eye. However, Sjögren's Syndrome-related dry eye has some specific features. In addition, the development of newer and safer therapeutic agents for Sjögren's syndrome-related dry eye is needed, and therefore further clinical, randomized studies are necessary.
BombardieriMArgyropoulouODFerroF, et al.One year in review 2020: pathogenesis of primary Sjögren's Syndrome. Clin Exp Rheumatol2021; 38: S3–S9.
2.
GeneraliECostanzoAMainettiC, et al.Cutaneous and mucosal manifestations of Sjögren's Syndrome. Clin Rev Allergy Immunol2017; 53: 357–370.
3.
StefanskiALTomiakCPleyerU, et al.The diagnosis and treatment of Sjögren's Syndrome. Dtsch Arztebl Int2017; 114: 354–361.
4.
KittridgeARouthouskaSBKormanNJ. Dermatologic manifestations of Sjögren syndrome. J Cutan Med Surg2011; 15: 8–14.
5.
FrançoisHMarietteX. Renal involvement in primary Sjögren syndrome. Nat Rev Nephrol [Internet]2016; 12: 82–93. Available from: https://doi.org/10.1038/nrneph.2015.174.
6.
ChungAWilgusMLFishbeinG, et al.Pulmonary and bronchiolar involvement in Sjogren's Syndrome. Semin Respir Crit Care Med2019; 40: 235–254.
7.
LeeOLTepelusTCHuangJ, et al.Evaluation of the corneal epithelium in non-Sjögren's And Sjögren's Dry eyes: an in vivo confocal microscopy study using HRT III RCM. BMC Ophthalmol2018; 18: 3–9.
8.
RouenPAWhiteML. Dry eye disease: prevalence, assessment, and management. Home Healthc Now2018; 36: 74–83.
9.
KassanSSMoutsopoulosHM. Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med2004; 164: 1275–1284.
10.
AkpekEKKlimavaAThorneJE, et al.Evaluation of patients with dry eye for presence of underlying Sjögren syndrome. Cornea2009; 28: 493–497.
11.
KruszkaPO’BrianRJ. Diagnosis and management of Sjögren syndrome. Am Fam Physician2009; 79: 465–470.
12.
AkpekEKBunyaVYSaldanhaIJ. Sjögren's syndrome: more than just dry eye. Cornea2019; 38: 658–661.
13.
AkpekEKMathewsPHahnS, et al.Ocular and systemic morbidity in a longitudinal cohort of Sjögren's Syndrome. Ophthalmology [Internet]2015; 122: 56–61. Available from: https://doi.org/10.1016/j.ophtha.2014.07.026.
14.
BunyaVYFernandezKBYingGS, et al.Survey of ophthalmologists regarding practice patterns for dry eye and Sjogren syndrome. Eye Contact Lens2018; 44: S196–S201.
15.
ThulasiPDjalilianAR. Update in current diagnostics and therapeutics of dry eye disease. Ophthalmology [Internet]2017; 124: S27–S33. Available from: https://doi.org/10.1016/j.ophtha.2017.07.022.
16.
CutoloCABarabinoSBonzanoC, et al.The use of topical corticosteroids for treatment of dry eye syndrome. Ocul Immunol Inflamm [Internet]2019; 27: 266–275. Available from: https://doi.org/10.1080/09273948.2017.1341988.
17.
ShiboskiCH, et al.2016 Classification criteria for primary Sjögren's Syndrome: a consensus and data-driven methodology involving three international patient cohorts. Accept Publ Ann Rheum Dis Arthritis Rheum2016; 69: 35–45.
18.
MarshallLLRoachJM. Treatment of dry eye disease. Consult Pharm2016; 31: 96–106.
19.
VehofJUtheimTPBootsmaH, et al.Advances, limitations and future perspectives in the diagnosis and management of dry eye in Sjögren's Syndrome. Clin Exp Rheumatol2021; 38: S301–S309.
20.
FoulksGNForstotSLDonshikPC, et al.Clinical guidelines for management of dry eye associated with Sjögren disease. Ocul Surf2015; 13: 118–132.
21.
LongQWangJYXuD, et al.Comparison of corneal biomechanics in Sjögren's Syndrome and non-Sjögren's Syndrome dry eyes by scheimpflug based device. Int J Ophthalmol2017; 10: 711–716.
22.
KangYSLeeHSLiY, et al.Manifestation of meibomian gland dysfunction in patients with Sjögren's Syndrome, non-Sjögren's Dry eye, and non-dry eye controls. Int Ophthalmol2018; 38: 1161–1167.
23.
PflugfelderSCJonesDJiZ, et al.Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjogren's Syndrome keratoconjunctivitis sicca. Curr Eye Res1999; 19: 201–211.
24.
AdatiaFAMichaeli-CohenANaorJ, et al.Correlation between corneal sensitivity, subjective dry eye symptoms and corneal staining in Sjögren's Syndrome. Can J Ophthalmol [Internet]2004; 39: 767–771. Available from: https://doi.org/10.1016/S0008-4182(04)80071-1.
25.
BronAJde PaivaCSChauhanSK, et al.TFOS DEWS II pathophysiology report. Ocul Surf [Internet]2017; 15: 438–510. Available from: https://doi.org/10.1016/j.jtos.2017.05.011.
26.
ChenXUtheimØAXiaoJ, et al.Meibomian gland features in a Norwegian cohort of patients with primary Sjögreńs syndrome. PLoS One2017; 12: 1–13.
27.
SullivanDADanaRSullivanRM, et al.Meibomian gland dysfunction in primary and secondary Sjögren syndrome. Ophthalmic Res2018; 59: 193–205.
28.
HwangJHLeeJHChungSH. Comparison of meibomian gland imaging findings and lipid layer thickness between primary Sjögren syndrome and non-Sjögren syndrome dry eyes. Ocul Immunol Inflamm [Internet]2020; 28: 182–187Available from: https://doi.org/10.1080/09273948.2018.1562557.
29.
WangYQinQLiuB, et al.Clinical analysis: aqueous-deficient and meibomian gland dysfunction in patients with primary Sjogren's Syndrome. Front Med2019; 6: 1–6.
30.
WhitcherJPShiboskiCHShiboskiSC, et al.A simplified quantitative method for assessing Keratoconjunctivitis Sicca from the Sjögren's Syndrome international registry. Am J Ophthalmol [Internet]2010; 149: 405–415. Available from: https://doi.org/10.1016/j.ajo.2009.09.013.
31.
CohenKL. Sterile corneal perforation after cataract surgery in Sjogren's Syndrome. Br J Ophthalmol1982; 66: 179–182.
32.
GottschJDAkpekEK. Topical cyclosporin stimulates neovascularization in resolving sterile rheumatoid central corneal ulcers. Trans Am Ophthalmol Soc2000; 98: 81–90.
33.
VivinoFBMinervaPHuangCH, et al.Corneal melt as the initial presentation of primary Sjögren's Syndrome. J Rheumatol2001; 28: 379–382.
34.
MurtaghPComerRFahyG. Corneal perforation in undiagnosed Sjögren's Syndrome following topical NSAID and steroid drops post routine cataract extraction. BMJ Case Rep2018; 2018: 1–3.
35.
BridgesAJBurnsRP. Acute iritis associated with primary Sjögren's Syndrome and high-titer anti—SS-A/Ro and anti—SS-B/La antibodies. Treatment with combination immunosuppressive therapy. Arthritis Rheum1992; 35: 560–563.
36.
ChoiWLeeSSParkYG, et al.A case of necrotizing keratoscleritis in primary Sjogren's Syndrome. Korean J Ophthalmol2011; 25: 275–277.
37.
BamroliaNRAroraRYadavaU. Unusual presentation of a case of Sjogren's Syndrome with neurological and ocular manifestation. Contact Lens Anterior Eye [Internet]2012; 35: 85–88. Available from: https://doi.org/10.1016/j.clae.2011.10.002.
38.
Fernandez CastroMSánchez-PiedraCAndreuJL, et al.Factors associated with severe dry eye in primary Sjögren's Syndrome diagnosed patients. Rheumatol Int [Internet]2018; 38: 1075–1082. Available from: https://doi.org/10.1007/s00296-018-4013-5.
39.
KimMKimHSNaKS. Correlation between tear osmolarity and other ocular surface parameters in primary Sjögren's Syndrome. Korean J Ophthalmol2017; 31: 25–31.
40.
Hernández-MolinaGLeal-AlegreGMichel-PeregrinaM. The meaning of anti-Ro and anti-La antibodies in primary Sjögren's Syndrome. Autoimmun Rev [Internet]2011; 10: 123–125. Available from: https://doi.org/10.1016/j.autrev.2010.09.001.
41.
FayyazAKurienBTScofieldRH. Autoantibodies in Sjögren's Syndrome. Rheum Dis Clin North Am2016; 42: 419–434.
42.
MavraganiCPTzioufasAGMoutsopoulosHM. Sjogren's syndrome: autoantibodies to cellular antigens: clinical and molecular aspects. Int Arch Allergy Immunol2000; 123: 46–57.
43.
LeeYJScofieldRHHyonJY, et al.Salivary chemokine levels in patients with primary Sjögren's Syndrome. Rheumatology2010; 49: 1747–1752.
44.
KangEHLeeYJHyonJY, et al.Salivary cytokine profiles in primary Sjögren's Syndrome differ from those in non-Sjögren sicca in terms of TNF-α levels and Th-1/Th-2 ratios. Clin Exp Rheumatol2011; 29: 970–976.
45.
LeeSYHanSJNamSM, et al.Analysis of tear cytokines and clinical correlations in Sjögren syndrome dry eye patients and non-Sjögren syndrome dry eye patients. Am J Ophthalmol [Internet]2013; 156: 247–253.e1. Available from: https://doi.org/10.1016/j.ajo.2013.04.003.
46.
ZhaoHLiQYeM, et al.Tear luminex analysis in dry eye patients. Med Sci Monit2018; 24: 7595–7602.
47.
ChenXAqrawiLAUtheimTP, et al.Elevated cytokine levels in tears and saliva of patients with primary Sjögren's Syndrome correlate with clinical ocular and oral manifestations. Sci Rep2019; 9: 1–10.
48.
LimSANamDHLeeJH, et al.Association of IL-21 cytokine with severity of primary Sjögren syndrome dry eye. Cornea2015; 34: 248–252.
49.
BunyaVYMassaro-GiordanoMVivinoFB, et al.Prevalence of novel candidate Sjögren syndrome autoantibodies in the Penn Sjögren's International collaborative clinical alliance cohort. Cornea2019; 38: 1500–1505.
50.
BunyaVYYingGSMaguireMG, et al.Prevalence of novel candidate sjogren syndrome autoantibodies in the dry eye assessment and management (DREAM) study. Cornea2018; 37: 1425–1430.
51.
HubschmanSRojasMKalavarM, et al.Association between early Sjögren markers and symptoms and signs of dry eye. Cornea2020; 39: 311–315.
52.
KarakusSBaerANAkpekEK. Clinical correlations of novel autoantibodies in patients with dry eye. J Immunol Res2019; 2019: 7935451.
53.
EverettSVishwanathSCaveroV, et al.Analysis of novel Sjogren's Syndrome autoantibodies in patients with dry eyes. BMC Ophthalmol2017; 17: 1–6.
54.
McNamaraNAGeSLeeSM, et al.Reduced levels of tear lacritin are associated with corneal neuropathy in patients with the ocular component of Sjögren's Syndrome. Investig Ophthalmol Vis Sci2016; 57: 5237–5243.
55.
PonziniEScottiLGrandoriR, et al.Lactoferrin concentration in human tears and ocular diseases: a meta-analysis. Investig Ophthalmol Vis Sci2020; 61: 9.
56.
WakamatsuTHDogruMMatsumotoY, et al.Evaluation of lipid oxidative stress status in Sjögren syndrome patients. Investig Ophthalmol Vis Sci2013; 54: 201–210.
57.
ShinzawaMDogruMDenS, et al.Epidermal fatty acid-binding protein: a novel marker in the diagnosis of dry eye disease in Sjögren syndrome. Int J Mol Sci2018; 19: 1–12.
58.
ZinkevičienėADumalakienėIMieliauskaitėD, et al.sICAM-1 as potential additional parameter in the discrimination of the Sjögren syndrome and non-autoimmune sicca syndrome: a pilot study. Clin Rheumatol2019; 38: 2803–2809.
59.
AqrawiLAChenXJensenJL, et al.Severity of clinical dry eye manifestations influences protein expression in tear fluid of patients with primary Sjögren's Syndrome. PLoS One2018; 13: 1–14.
60.
LiangHKessalKRabutG, et al.Correlation of clinical symptoms and signs with conjunctival gene expression in primary Sjögren syndrome dry eye patients. Ocul Surf [Internet]2019; 17: 516–525. Available from:https://doi.org/10.1016/j.jtos.2019.03.005.
PuckerAMarroneMNicholsJJ. Over the counter (OTC) artificial tear drops for dry eye syndrome. Cochrane Database Syst Rev2016: 2: CD009729.
63.
ZhangYPotvinRGongL. A study of the short-term effect of artificial tears on contrast sensitivity in patients with Sjögren's Syndrome. Investig Ophthalmol Vis Sci2013; 54: 7977–7982.
64.
CourseyTGde PaivaCS. Managing Sjögren's Syndrome and non-Sjögren syndrome dry eye with anti-inflammatory therapy. Clin Ophthalmol2014; 8: 1447–1458.
65.
BhojwaniRCellesiFMainoA, et al.Treatment of dry eye: an analysis of the British Sjögren's Syndrome association comparing substitute tear viscosity and subjective efficacy. Contact Lens Anterior Eye [Internet]2011; 34: 269–273. Available from: https://doi.org/10.1016/j.clae.2011.05.003.
66.
GuideraACLuchsJIUdellIJ. Associated with topical nonsteroidal anti-inflammatory drugs. Cornea2001; 6420: 936–944.
67.
AragonaPStiloAFerreriF, et al.Effects of the topical treatment with NSAIDs on corneal senstivity and ocular surface and Sjögren's Syndrome patients. Eye2005; 19: 535–539.
68.
CubukMOUcgulAYOzgurA, et al.Topical cyclosporine a (0.05%) treatment in dry eye patients: a comparison study of Sjogren's Syndrome versus non-Sjogren's Syndrome. Int Ophthalmol [Internet]2021; 41: 1479–1485Available from: https://doi.org/10.1007/s10792-021-01708-1.
69.
OgawaYOkamotoSMoriT, et al.Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant2003; 31: 579–583.
70.
KojimaTIshidaRDogruM, et al.The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Ophthalmol2005; 139: 242–246.
71.
LiuYHirayamaMCuiX, et al.Effectiveness of autologous serum eye drops combined with punctal plugs for the treatment of Sjögren syndrome-related dry eye. Cornea2015; 34: 1214–1220.
72.
KunzMIbrahimSM. Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity. Mediators Inflamm2009; 2009: 979258.
73.
RoescherNTakPPIlleiGG. Cytokines in Sjögren's Syndrome. Oral Dis2009; 15: 519–526.
74.
HwangJChungSHJeonS, et al.Comparison of clinical efficacies of autologous serum eye drops in patients with primary and secondary Sjögren syndrome. Cornea2014; 33: 663–667.
75.
Sanchez-AvilaRMMerayo-LlovesJRiestraAC, et al.The effect of immunologically safe plasma rich in growth factor eye drops in patients with Sjögren syndrome. J Ocul Pharmacol Ther2017; 33: 391–399.
76.
CaginiCTorroniGFioreT, et al.Tear film stability in Sjögren syndrome patients treated with hyaluronic acid versus crosslinked hyaluronic acid-based eye drops. J Ocul Pharmacol Ther2017; 33: 539–542.
77.
JumblattJEJumblattMM. Regulation of ocular mucin secretion by P2Y2 nucleotide receptors in rabbit and human conjunctiva. Exp Eye Res1998; 67: 341–346.
78.
LiYKuangKYerxaB, et al.Rabbit conjunctival epithelium transports fluid, and P2Y22 receptor agonists stimulate cl- and fluid secretion. Am J Physiol - Cell Physiol2001; 281: 595–602.
79.
MurakamiTFujiharaTHoribeY, et al.Diquafosol elicits increases in net cl- transport through P2Y2 receptor stimulation in rabbit conjunctiva. Ophthalmic Res2004; 36: 89–93.
80.
KohSIkedaCTakaiY, et al.Long-term results of treatment with diquafosol ophthalmic solution for aqueous-deficient dry eye. Jpn J Ophthalmol2013; 57: 440–446.
81.
WuDChenWQLiR, et al.Efficacy and safety of topical diquafosol ophthalmic solution for treatment of dry eye: a systematic review of randomized clinical trials. Cornea2015; 34: 644–650.
82.
YokoiNSonomuraYKatoH, et al.Three percent diquafosol ophthalmic solution as an additional therapy to existing artificial tears with steroids for dry-eye patients with Sjögren's Syndrome. Eye2015; 29: 1204–1212.
83.
JeonHSHyonJY. The efficacy of diquafosol ophthalmic solution in non-Sjögren and Sjögren syndrome dry eye patients unresponsive to artificial tear. J Ocul Pharmacol Ther2016; 32: 463–468.
84.
GoliasCHTsoutsiEMatziridisA, et al.Leukocyte and endothelial cell adhesion molecules in inflammation focusing on inflammatory heart disease. In Vivo (Brooklyn)2007; 21: 757–770.
85.
Contreras-RuizLMirFATurpieB, et al.Sjögren's syndrome associated dry eye in a mouse model is ameliorated by topical application of integrin α4 antagonist GW559090. Exp Eye Res [Internet]2016; 143: 1–8. Available from: https://doi.org/10.1016/j.exer.2015.10.008.
86.
MillerDHKhanOASheremataWA, et al.A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2003; 348: 15–23.
87.
PonticelliCMoroniG. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf [Internet]2017; 16: 411–419. Available from: https://doi.org/10.1080/14740338.2017.1269168.
88.
SchrezenmeierEDörnerT. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol2020; 16: 155–166.
89.
YavuzSAsfuroğluEBicakcigilM, et al.Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren's Syndrome. Rheumatol Int2011; 31: 1045–1049.
90.
YoonCHLeeHJLeeEY, et al.Effect of hydroxychloroquine treatment on dry eyes in subjects with primary Sjögren's Syndrome: a double-blind randomized control study. J Korean Med Sci2016; 31: 1127–1135.
91.
WangSQZhangLWWeiP, et al.Is hydroxychloroquine effective in treating primary Sjogren's Syndrome: a systematic review and meta-analysis. BMC Musculoskelet Disord2017; 18: 1–13.
MammanaSGugliandoloACavalliE, et al.Human gingival mesenchymal stem cells pretreated with vesicular moringin nanostructures as a new therapeutic approach in a mouse model of spinal cord injury. J Tissue Eng Regen Med2019; 13: 1109–1121.
94.
MeiselRZibertALaryeaM, et al.Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood2004; 103: 4619–4621.
95.
CaglianiJGrandeDMolmentiEP, et al.Immunomodulation by mesenchymal stromal cells and their clinical applications. J Stem Cell Regen Biol 2017; 3: 10.15436/2471-0598.17.022.
96.
AbughanamGElkashtyOALiuY, et al.Mesenchymal stem cells extract (MSCsE)-based therapy alleviates xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome-like disease. Int J Mol Sci2019; 20: 4750.
97.
De VitaSQuartuccioLSerorR, et al.Efficacy and safety of belimumab given for 12 months in primary Sjögren's Syndrome: the BELISS open-label phase II study. Rheumatol (United Kingdom)2015; 54: 2249–2256.
98.
MarietteXRavaudPSteinfeldS, et al.Inefficacy of infliximab in primary Sjögren's Syndrome: results of the randomized, controlled trial of remicade in primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum2004; 50: 1270–1276.
99.
SteinfeldSDTantLBurmesterGR, et al.Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's Syndrome: an open-label phase I/II study. Arthritis Res Ther2006; 8: 1–11.
100.
Do Valle SouzaFBPorfírioGJMNazaréB, et al.Rituximab effectiveness and safety for treating primary Sjögren's Syndrome (pSS): systematic review and meta-analysis. PLoS One. 2016; 11: 1–12.
101.
KawakitaTShimmuraSTsubotaK. Effect of oral pilocarpine in treating severe dry eye in patients with sjogren syndrome. Asia-Pacific J Ophthalmol2015; 4: 101–105.
Trujillo-VargasCMKutlehriaSHernandezH, et al.Rapamycin eyedrops increased cd4+foxp3+cells and prevented goblet cell loss in the aged ocular surface. Int J Mol Sci2020; 21: 1–17.
104.
ShahMEdmanMCJangaSR, et al.Rapamycin eye drops suppress lacrimal gland inflammation in a murine model of Sjögren's Syndrome. Investig Ophthalmol Vis Sci2017; 58: 372–385.
105.
WangSWangMLiuY, et al.Effect of rapamycin microspheres in Sjögren syndrome dry eye: preparation and outcomes. Ocul Immunol Inflamm [Internet]2019; 27: 1357–1364Available from: https://doi.org/10.1080/09273948.2018.1527369.
106.
GodinMRStinnettSSGuptaPK. Outcomes of thermal pulsation treatment for dry eye syndrome in patients with sjogren disease. Cornea2018; 37: 1155–1158.
107.
TincaniAAndreoliLCavazzanaI, et al.Novel aspects of Sjögren's Syndrome in 2012. BMC Med2013; 11: 93.
108.
LeeJHKimSJByunYS, et al.The association of Serum vitamin D level with the severity of dry eye parameters in primary Sjögren syndrome. Cornea2020; 39: 702–705.
109.
KuoCYHuangYCLinKJ, et al.Vitamin d deficiency is associated with severity of dry eye symptoms and primary Sjögren's Syndrome: a systematic review and meta-analysis. J Nutr Sci Vitaminol (Tokyo)2020; 66: 386–388.
